Syncona appoints John Roche as an independent Non-Executive Director

Syncona
[shareaholic app="share_buttons" id_name="post_below_content"]

Syncona Ltd (LON:SYNC), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, has announced the appointment of John Roche as an independent Non-Executive Director, with effect from 1 October 2024.

John brings many years of broad financial experience to the role, having spent more than 15 years as a Partner at PricewaterhouseCoopers (PwC) in Guernsey. During this time he served as managing partner of the Guernsey office for seven years and was leader of the Capital Markets Practice for twelve years. While at PwC, John specialised in providing audit and capital markets advisory services to listed investment companies and alternative asset management clients, developing extensive valuation experience.

John is a Fellow of the Institute of Chartered Accountants in Ireland, who retired from practice in 2022. He is a Non-Executive Director and Chair of the Audit Committee of Riverstone Energy Limited, a London-listed investment company, and a Guernsey resident.

On appointment, John will join the Company’s Audit Committee.

Melanie Gee, Chair of Syncona Ltd, said: “We are delighted to welcome John to Syncona. He brings significant financial experience to the Board, and we look forward to benefitting from his breadth of knowledge and expertise as we support the Syncona team to deliver our long-term strategy and growth ambitions.”

John Roche said: “I am delighted to be joining Syncona. I look forward to working closely with my Board colleagues and the broader Syncona team as they continue to invest to extend and enhance human life.”

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases.
    Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases.
    Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations.
    Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment
    Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease.

      Search

      Search